<div id="readability-page-1"><p><span>Humana (NYSE:HUM - Get Free Report)</span> had its price target lowered by stock analysts at Morgan Stanley  from $277.00 to $262.00 in a report released on Wednesday,MarketScreener reports. The firm presently has an &#34;equal weight&#34; rating on the insurance provider's stock. Morgan Stanley's price objective indicates a potential upside of 1.62% from the company's current price.</p><ul><li>UnitedHealth Group: Pariah to Pole Position to Buy the Dip Levels</li></ul><p>Several other analysts have also issued reports on the stock. KeyCorp  restated a &#34;sector weight&#34; rating on shares of Humana in a report on Friday. Truist Financial dropped their price target on Humana from $300.00 to $285.00 and set a &#34;hold&#34; rating on the stock in a research note on Monday, November 10th. Bank of America lifted their target price on Humana from $280.00 to $300.00 and gave the company a &#34;neutral&#34; rating in a research note on Friday, October 10th. The Goldman Sachs Group lowered their price objective on Humana from $235.00 to $215.00 and set a &#34;sell&#34; rating on the stock in a report on Monday, November 24th. Finally, Wells Fargo &amp; Company lifted their price target on shares of Humana from $344.00 to $347.00 and gave the company an &#34;overweight&#34; rating in a research report on Tuesday, October 7th. Nine research analysts have rated the stock with a Buy rating, ten have assigned  a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the company  has a consensus rating of &#34;Hold&#34; and a consensus target price of $294.32.</p><p><b>Check Out Our Latest Stock Analysis on HUM</b></p><h2>Humana Price Performance</h2><ul><li>2 Healthcare Recession-Resistant Stocks Unaffected by Tariffs</li></ul><p>Shares of HUM opened at $257.83 on Wednesday. Humana has a fifty-two week low of $206.87 and a fifty-two week high of $315.35. The company has a 50 day moving average price of $261.24 and a 200-day moving average price of $259.00. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.02 and a current ratio of 2.02. The stock has a market capitalization of $31.01 billion, a PE ratio of 24.14, a PEG ratio of 1.61 and a beta of 0.46. </p><p>Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The insurance provider reported $3.24 EPS for the quarter, topping analysts' consensus estimates of $2.95 by $0.29. The company had revenue of $32.65 billion during the quarter, compared to analysts' expectations of $31.99 billion. Humana had a return on equity of 12.86% and a net margin of 1.02%.The firm's revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.16 EPS.  Equities analysts predict that  Humana will post 16.47 earnings per share for the current fiscal year. </p><h2>Institutional Investors Weigh In On Humana</h2><ul><li>MarketBeat Week in Review – 02/17 - 02/21</li></ul><p>A number of large investors have recently added to or reduced their stakes in HUM. Elevation Point Wealth Partners LLC purchased a new position in shares of  Humana during the 2nd quarter valued at approximately $32,000.  Mather Group LLC. bought a new stake in shares of  Humana in the 3rd quarter worth about $34,000.  AlphaCore Capital LLC acquired a new stake in shares of  Humana in the 2nd quarter valued at about $39,000.  Private Wealth Management Group LLC lifted its position in shares of  Humana by 47.5% during the third quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider's stock worth $39,000 after purchasing an additional 48 shares during the last quarter.  Finally, Larson Financial Group LLC increased its holdings in  Humana by 114.1% in the third quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider's stock valued at $40,000 after buying an additional 81 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds. </p><h2>Humana Company Profile</h2> (Get Free Report)<p>Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Humana</li><li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li><li>3 Tech Stocks Down Over 60%—Which One Is Worth Buying?</li><li>3 Dividend Kings To Consider</li><li>25 Years Later, Cisco Finally Recovers From the Dot-Com Crash</li><li>3 Warren Buffett Stocks to Buy Now</li><li>AI Chips Can’t Exist Without These 2 Underrated Tech Giants</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhVTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhVTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Humana Right Now?</h2><p>Before you consider Humana, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.</p><p>While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Morgan Stanley has lowered its price target for Humana from $277.00 to $262.00 and assigned an 'equal weight' rating. Other analysts have also adjusted their ratings and price targets for Humana. The stock opened at $257.83 on Wednesday, with a 52-week range of $206.87 to $315.35. Humana reported strong quarterly earnings, with revenue up 11.1% year-over-year. Institutional investors have been adjusting their stakes in the company.</p>

Morgan Stanley Has Lowered Expectations for Humana (NYSE:HUM) Stock Price